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Abstract
Rational: Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are emerging problems in several
countries. These infections require long and expensive treatment regimens. Recently, 2 new drugs, bedaquiline and delamanid, have
been approved in several countries for use in adults with severe, difﬁcult-to-treat MDR-TB, and it has been suggested that they could
also be administered to children with MDR-TB and limited treatment options. However, no study has been completed on their efﬁcacy.
Patient concerns: This report describes a 12-year-old child with XDR-TB who was cured after a 24-month therapy regimen,
which included delamanid.
Diagnoses: The patient showed progressive clinical deterioration after 5 months of treatment with the majority of anti-TB drugs
available on the market.
Interventions: After unsuccessfull treatment with several anti-TB drugs for 5 months, he was treated with a regimen including for
24 months.
Outcomes:Direct smear microscopy of the gastric aspirates and gastric aspirate cultures forMycobacterium tuberculosis became
negative after only 1 week and remained persistently negative. During the 24-month treatment, all blood test results remained within
the normal range, no adverse events were reported, and corrected QT interval was always normal. A clinical and laboratory control
was performed 3 months after discontinuation of delamanid, and the other drugs did not reveal any modiﬁcation of both general
conditions as well as laboratory and radiological ﬁndings. The patient was considered cured.
Lessons: The positive outcome associated with the favorable safety and tolerability proﬁle showed that long-term therapy with
delamanid can signiﬁcantly contribute to treating apparently hopeless XDR-TB cases in children.
Abbreviations: CRP = C-reactive protein, CT = chest computerized tomography, DST = drug susceptibility testing, ECG =
electrocardiography, IGRA = interferon-g-release assay, MDR = multidrug-resistant, PAS = para-aminosalicylic acid, QTc =
corrected QT interval, TB = tuberculosis, TST = tuberculin skin test, WBC = white blood cells, XDR = extensively drug-resistant
tuberculosis.
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tuberculosis1. Introduction
A recent review of the available data estimated that approxi-
mately 32,000 children worldwide suffer from multidrug-
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the available anti-TB drugs is challenging. These infections
require long and expensive treatment regimens and are associated
with severe adverse events and very low cure rates.[2] Recently, 2
new drugs, bedaquiline and delamanid, have been approved in
several countries for use in adults with severe, difﬁcult-to-treat
MDR-TB, and it has been suggested that they could also be
administered to children with MDR-TB and limited treatment
options.[3] However, no study has been completed on bedaquiline
in children to date.[4] In contrast, several clinical trials have tested
the pharmacokinetics and safety of delamanid in children, but no
data are available on delamanid efﬁcacy in children.[5–7]
Delamanid is a nitro-dihydro-imidazoxazole derivative with
mycobacteria-speciﬁc antibacterial activity in vitro, without
activity against Gram-positive or Gram-negative bacteria or
intestinal ﬂora.[8] The nitroimidazopyran derivative acts through
the inhibition of the mycolic acid biosynthesis, thus preventing
the formation of the mycobacterial cell envelope and secondly,
facilitating better drug penetration.[8]
In a number of cases, compassionate use of delamanid was
authorized by the producer after approval by an independent
panel of experts after assessment of the appropriateness of the
request.[9] One of these children with XDR-TB successfully
completed a 24-month therapeutic regimen including delamanid
during the entire duration of treatment, a period longer than any
other pediatric treatment with this drug. This report describes the
impact of the drug on the clinical course of the disease in this
patient and the delamanid safety and tolerability during this long
period of drug administration.2. Case
2.1. Presenting concerns
The patient (male, 12 years’ old), native Italian, without
comorbidities or risk factors for TB, was diagnosed in October
2013 in Milan (Italy) with both laryngeal and pulmonary TB.
Clinical history was negative for relevant problems until May
2013, when he began to suffer from progressive dysphonia
associated with asthenia and weakness in the absence of fever.2.2. Clinical ﬁndings
When the pediatric infectious disease specialist visited the child, a
chest radiograph was requested, and it showed extensive
bronchial wall thickening with peribronchial vascular distribu-
tion in both lungs. A chest computerized tomography (CT) was
requested, and it showed bilateral multiple nodular and
pseudonodular inﬁltrates, with ﬁbrotic and calciﬁed areas; no
excavations were recognizable, and several enlarged lymph nodes
without signs of colliquation were present in the mediastinum
and in both of the laterocervical regions. The aryepiglottic fold
was thickened. Blood examinations were performed and they
showed white blood cells (WBC) count and C-reactive protein
(CRP) in normal range (WBC: 6300cells/mL; CRP: 0.19mg/dL).
In addition, routine biochemical blood examinations were
normal. However, on the basis of CT ﬁndings, laryngeal and
pulmonary TB was suspected, and the patient was hospitalized.2.3. Diagnostic focus and assessment
A tuberculin skin test (TST) was negative when requested,
whereas an interferon-g-release assay (IGRA; QuantiFERON2GOLD, Qiagen, GmbH, Hilden, Germany) showed positive
results. Direct smear microscopy of gastric aspirates for acid-fast
bacilli and gastric aspirate cultures for M tuberculosis were
positive. Based on early detection of rifampicin resistance by
Xpert MTB/RIF (Cepheid, Sunnyvale, CA), initially (October 4,
2013) the child was treated with high-dose isoniazid, ethambutol,
pyrazinamide, and moxiﬂoxacin. However, because drug
susceptibility testing (DST) revealed that the strain was resistant
to all ﬁrst- and second-line drugs except para-aminosalicylic acid
(PAS) and linezolid, the regimen was redesigned, and PAS,
linezolid, terizidone, clarithromycin, amoxicillin-clavulanate,
and moxiﬂoxacin were prescribed (October 30, 2013). After 4
weeks of treatment, both clinical and radiological improvements
were achieved and laboratory examinations remained stable.
Moreover, the smear microscopy of the gastric aspirate remained
positive, but showed a reduced mycobacterial burden. The
patient was sent home with the same drug therapy.2.4. Therapeutic focus and assessment
Despite good treatment adherence, the patient experienced
progressive clinical deterioration, with loss of 4-kg body weight
(starting from a weight of 36kg) in <2 months and evident
asthenia and weakness. Hemoglobin decreased to approximately
2.5g/dL with WBC count and CRP in normal range, and smear
microscopy on direct gastric aspirate showed again positivity
with high grading. He was re-admitted to the hospital. Blood
transfusions were administered, and parenteral nutrition was
initiated. On February 9, 2014, isoniazid, meropenem, amikacin,
clofazimine, and ethionamide were added to the previous anti-TB
therapy. However, 10 days later, all anti-TB drugs were stopped
because the patient experienced acute pancreatic insufﬁciency.
On March 1, on the basis of recommendations from the TB
Consilium platform and 4 experts in pediatric MDR/XDR-TB
management,[10] after the approval of the Ethics Committee of
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
and the signature of a written consent from both the parent and a
written assent from the child, anti-TB drugs were progressively
reintroduced. Amoxicillin-clavulanate (100mg/kg/day as amoxi-
cillin i.v.), meropenem (100mg/kg/day i.v.), linezolid (300mg/
day i.v.), clofazimine (100mg/day by mouth), PAS (8g/day by
mouth), and ethionamide (250mg/day by mouth) were chosen.
Moreover, delamanid, obtained from the manufacturer for
compassionate use, was added at the dose of 100mg twice daily
by mouth.
This regimen was maintained for 3 months, and signiﬁcant
changes in the clinical and laboratory data were observed.
General conditions, including weight, signiﬁcantly improved,
blood hemoglobin returned to normal values, and the patient
never had fever. Direct smear microscopy of the gastric aspirates
and gastric aspirate cultures for M tuberculosis became negative
after only 1 week and remained persistently negative. All blood
test results remained within the normal range, no adverse events
were reported, and corrected QT interval (QTc) was always
normal. Meropenem and amoxicillin-clavulanate were then
discontinued before the discharge from the hospital, and the
patient continued the other 5 drugs, including delamanid. A chest
CT obtained before discharge documented a signiﬁcant improve-
ment in the previously described radiological ﬁndings with a
reduction in the tree-in-bud signs in the right upper lobe and in
the reticulonodular opacity in both upper lobes and lingula.Most
of the lesions were described as ﬁbrotic. The patient was
discharged from the hospital on May 31.
[11]
Table 1
Clinical and laboratory data of the 12-year-old child with extensively drug-resistant (XDR) tuberculosis during the 24-month regimen
including delamanid.
Data T0 days T7 days T30 days T60 days T90 days T6 Mo T12 Mo T18 Mo T24 Mo
Symptoms Asthenia, weakness Asthenia None None None None None None None























WBC, cell/mL 6060 11,120 6880 5950 6740 5820 6210 7090 6180
Neutrophils, % 30.6 56.3 53.6 41.7 43.8 41.1 54.6 59.4 48.5
Hb, g/dL 11 14.2 15.4 16 14.4 13.3 13.8 14.9 14.4
CRP, mg/dL 0.11 0.03 <0.03 <0.03 0.11 0.03 0.05 0.1 0.06
Urea, mg/dL 27 31 23 27 31 22 33 40 28
Creatinine, mg/dL 0.41 0.38 0.42 0.45 0.54 0.67 0.65 0.7 0.67
AST, U/L 11 13 28 56 16 19 22 25 31
ALT, U/L 14 14 37 121 20 14 18 16 32
Na, mEq/L 139 135 139 138 142 142 141 143 142
K, mEq/L 4.40 4.34 4.37 4.49 4.17 4.38 4.83 4.7 4.8
Cl, mEq/L 108 99 103 103 103 105 104 103 103
Ca, mEq/L 9.5 9.9 9.2 9.2 9 8.1 9.06 9.06 6.7
Mg, mEq/L 1.76 2.03 2.03 1.88 — — — — —
Amylase, U/L 143 71 53 62 49 61 63 70 70
Lipase, U/L 270 70 10 26 16 17 20 26 27
Albumin, mg/dL 4 4.8 4.1 4 4 4.3 4.4 4.5 4.5
QTc, ms 426 435 444 410 415 416 445 429 436
ALT= alanine aminotransferase, AST=aspartate aminotransferase, Ca= calcium, Cl= chloride, CRP=C-reactive protein, Hb=hemoglobin, K=potassium, Mg=magnesium, Na= sodium, QTc=corrected QT
interval, WBC=white blood cells.
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During the treatment period, the child completed routine
monthly visits, periodic blood tests (including complete blood
cell count and blood chemistry tests), and monthly electrocardi-
ography (ECG) for QTc screening for early detection of any signs
of adverse events. He persisted in good general conditions with
negative results of gastric aspirate (microscopy and culture),
normal blood laboratory tests, and normal QTc. Neutropenia
never developed, and the liver and kidney function tests were
always normal. Moreover, the QTc interval was never found to
be>500ms. Moreover, chest magnetic resonance imaging (MRI)
performed after 18 months from the beginning of delamanid
regimen revealed parenchymal consolidation and reticulonodular
opacity predominantly in right upper lobe and lingua, with
ﬁbrotic bronchial dilatation and mediastinal lymphadenopathy
with small lymph nodes. Consequently, ethionamide and
clofazimine were suspended, and treatment with PAS, linezolid,
and delamanid was maintained for a total of 24 months. Before
discontinuation, a chest MRI conﬁrmed that no signs of negative
evolution of the previously described lesions had occurred and
that no new lesions were evident.
A clinical and laboratory control performed 3 months after
discontinuation of delamanid, PAS, and linezolid did not reveal
any modiﬁcation of both general conditions as well as laboratory
and radiological ﬁndings. The patient was considered cured.
2.6. Timeline
Table 1 summarizes the clinical and laboratory data of the child.3. Discussion
Clinical trials with delamanid carried out in adults with MDR/
XDR-TB receiving 100 or 200mg twice a day of this drug added
to a standardized background therapy have shown that it is3effective, safe, and well tolerated. The results indicate that
delamanid reduced the rates of positive cultures after only 2
months of administration. However, better results were achieved
when delamanid was administered for 6 months or 8 months
with a break in the middle. With the latter regimen, there was a
higher reduction in positive cultures and a relevant impact on
mortality.[12] The safety data were reassuring because the most
common adverse events following delamanid administration
were nausea, vomiting, and dizziness, which were observed in
approximately one-third of treated adults, but they were usually
mild and did not lead to treatment discontinuation. The only
troubling side effect of this drug was QT prolongation that was
observed in approximately 10% of the treated subjects and was
apparently related to the dose.[12] However, data regarding the
use of delamanid for periods >6 months have not been reported.
Moreover, data collected in children, which are limited in number
andweremainly obtained in adolescents receiving 100mg 2 times
daily, do not allow for deﬁnitive conclusions regarding efﬁcacy.
This is the ﬁrst case showing that delamanid can signiﬁcantly
contribute to treating for several months apparently hopeless
XDR-TB cases with a favorable safety and tolerability proﬁle.
Long-term prescription of anti-TB drugs is common in patients
with MDR/XDR-TB.[13] However, the long duration of
treatment, the toxicity of certain drugs, and the high cost
discourage many patients and pose a major challenge to the
health system. This explains why recently the World Health
Organization (WHO) has recommended a standardized treat-
ment regimen for MDR-TB lasting no >9 months: kanamycin,
moxiﬂoxacin, prothionamide, clofazimine, high-dose isoniazid,
pyrazinamide, and ethambutol given together in an initial phase
of 4 months, followed by 5 months of treatment with 4 of the
drugs (e.g., moxiﬂoxacin, clofazimine, pyrazinamide, and
ethambutol).[13] Although this regimen has resulted in high rates
of relapse-free cures in selected MDR-TB patients with an
acceptable safety proﬁle, it is not indicated in very complicated
Esposito et al. Medicine (2016) 95:46 Medicinecases, such as the one reported in this study. The presence of a
strain resistant to one of the drugs included in the WHO regimen
together with an extrapulmonary localization of the infection are
2 of the conditions that contraindicate the WHO suggested
regimen.[13] Consequently, particularly in subjects with XDR-
TB, the use of long-term treatment with effective drugs remains
the major recommended treatment. The case here described
shows that delamanid was effective and well tolerated even when
provided for 24 months.
In conclusion, delamanid is active against XDRM tuberculosis
and can be considered for selected children with very difﬁcult-to-
treat diseases. Future studies investigating the long-term use of
delamanid in children are needed. They may help solve any
potential problems of effectiveness and safety of this drug in the
pediatric population of any age and permit delamanid inclusion
in the armamentarium of drugs useful for controlling severe
pediatric cases of XDR-TB.3.1. Patient’s parents’ perspective
Wewere very worried when we were informed of the XDR-TB in
our child. In particular, we were worried after the second
hospitalization when his clinical conditions were rapidly
worsening. We were conﬁdent in the pediatricians who followed
our child, and we were very happy to discover that delamanid
was able to negativize the gastric aspirate. The treatment was
long, but we are really happy considering the results!3.2. Informed consent
The patient’s parents provided their written informed consent for
the publication of this study.Acknowledgments
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